Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors

Neurology

Volumn 80, Issue 17, 2013, Pages 1598-1605

  Nayak, Lakshmi ^a,b   Fleisher, Martin ^a   Gonzalez Espinoza, Rita ^a   Lin, Oscar ^a   Panageas, Katherine ^a   Reiner, Anne ^a   Liu, Chhui Mei ^a   De Angelis, Lisa M ^a   Omuro, Antonio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

ARTICLE; ATAXIA; BREAST CANCER; CARCINOID; CELL CULTURE; CELL DIFFERENTIATION; CEREBROSPINAL FLUID CYTOLOGY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EPENDYMOMA; GLIOBLASTOMA; GLIOMA; HUMAN; HYDROCEPHALUS; LEPTOMENINGEAL METASTASIS; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MELANOMA; MENINGEAL METASTASIS; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PILOT STUDY; PLEOCYTOSIS; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; UTERINE CERVIX CANCER; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID; CYTODIAGNOSIS; FEMALE; IMMUNOMAGNETIC SEPARATION; MALE; METASTASIS; METHODOLOGY; NEOPLASM; PATHOLOGY; TUMOR EMBOLISM;

CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; MALE; MENINGEAL CARCINOMATOSIS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS;

MLCS; MLOWN;

EID: 84878936362     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828f183f     Document Type: Article

References (30)

1. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 2005;75:85-99.
2. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-772.
3. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979;29:1369-1375.
4. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-6904.
5. Scher HI, Jia X, De Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233-239.
6. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
7. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-128.
8. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-7058.
9. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell-Search system. Clin Cancer Res 2007;13:920-928.
10. Kleinschmidt-De Masters BK, Damek DM. The imaging and neuropathological effects of bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol 2010;96:375-384.
11. Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009;36:S35-S45.
12. Herrlinger U, Forschler H, Kuker W, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004;223:167-178.
13. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology 2010;74:1449-1454.
14. Waki F, Ando M, Takashima A, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 2009;93:205-212.
15. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7:382-385.
16. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103:2344-2348.
17. Enting RH. Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res 2005;125:17-30.
18. Bach F, Bjerregaard B, Soletormos G, Bach FW, Horn T. Diagnostic value ofcerebrospinal fluid cytology in comparison with tumor marker activity in central nervous system metastases secondary to breast cancer. Cancer 1993;72:2376-2382.
19. Corsini E, Bernardi G, Gaviani P, et al. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med 2009;47:874-879.
20. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000;54:1670-1676.
21. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 2004;91:219-224.
22. Reijneveld JC, Brandsma D, Boogerd W, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005;65:1120-1122.
23. Van De Langerijt B, Gijtenbeek JM, De Reus HP, et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 2006;67:114-119.
24. Groves MD, Hess KR, Puduvalli VK, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009;94:229-234.
25. Brandsma D, Voest EE, De Jager W, et al. CSF protein profiling using Multiplex Immuno-assay: a potential new diagnostic tool for leptomeningeal metastases. J Neurol 2006;253:1177-1184.
26. Straathof CS, De Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999;246:810-814.
27. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Monting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis: a single centre experience. Br J Haematol 2004;124:762-768.
28. Freilich RJ, Krol G, De Angelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-57.
29. Patel AS, Allen JE, Dicker DT, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2011;2:752-760.
30. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010;20:96-99.